Clinical trials: Recurrent GBM
Grade IV Glioma, Grade IV Astrocytoma
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01290692
- Testing
- TVI-Brain-1
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- TVAX Biomedical
Adult Brain Glioblastoma
Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
This phase II trial studies how well methoxyamine works when added to standard temozolomide in treating patients with glioblastoma that has come back.
- Trial name
- NCT02395692
- Testing
- Treatment, Methoxyamine, Temozolomide
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Malignant Glioma
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory).
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT02208362
- Testing
- Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- City of Hope Medical Center
Brain Cancer, Glioblastoma
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
The goal of this clinical research study is to learn if the combination of bevacizumab and lomustine can help to control glioblastoma. The safety of this combination will also be studied.
- Trial name
- NCT01067469
- Testing
- Standard Dose Bevacizumab, Low Dose Bevacizumab, Lomustine
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms
Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Single-agent, open-label, multi-center sequential dose escalation and expansion study of BAL101553, administered as an intravenous (IV) infusion over 48 hours to adults with advanced or recurrent solid tumors or recurrent…
- Trial name
- NCT02895360
- Testing
- BAL101553, BAL101553 at MTD
- Where
- 6 sites in Switzerland
- Volunteers
- 43 people
- Sponsor
- Basilea Pharmaceutica
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498927
- Testing
- temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, Astrocytoma
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.
- Conditions
- Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, Recurrent
- Trial name
- NCT00575887
- Testing
- Temozolomide
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Marmara University
Recurrent Glioblastoma
Ketogenic Diet for Recurrent Glioblastoma
To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma
- Trial name
- ERGO (NCT00575146)
- Testing
- TAVARLIN
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Glioblastoma
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent…
- Trial name
- NCT03149003
- Testing
- DSP-7888 Dosing Emulsion, Bevacizumab
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- Sumitomo Pharma America, Inc.
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Pazopanib in Treating Patients With Recurrent Glioblastoma
This phase II trial is studying the side effects and how well pazopanib works in treating patients with recurrent glioblastoma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00459381
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01648348
- Testing
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis
- Where
- 308 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioblastoma
Infigratinib in Recurrent High-Grade Glioma Patients
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for…
- Conditions
- Glioma, Glioblastoma, GBM
- Trial name
- NCT04424966
- Testing
- Infigratinib
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Nader Sanai
Glioblastoma Multiforme, Glioma
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Current treatments for Glioblastoma Multiforme (GBM), the most common and malignant primary brain tumor are inadequate and as such, the median survival for most patients with GBM is on the order of months, even after…
- Conditions
- Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
- Trial name
- NCT01044966
- Testing
- ITV DepoCyt + Temozolomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Anaplastic Glioma of Brain, Glioblastoma Multiforme
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent…
- Conditions
- Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
- Trial name
- NCT00504660
- Testing
- Capecitabine, Celecoxib (Celebrex), Temozolomide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
The purpose of this study is to investigate the safety and performance of an investigational agent, known as 5-ALA or Gliolan (aminolevulinic acid), that many be useful to a surgeon for visualizing a tumor during surgery.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01575275
- Testing
- aminolevulinic acid, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Michael Vogelbaum, MD, PhD
Recurrent Glioblastoma
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.
- Trial name
- NCT03430791
- Testing
- Nivolumab 240 mg IV, Nivolumab 3 mg/kg, Ipilimumab 1 mg/kg
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Baptist Health South Florida
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come…
- Conditions
- Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma
- Trial name
- NCT02192359
- Testing
- Carboxylesterase-expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT.
- Trial name
- NCT01966809
- Testing
- Photofrin photodynamic therapy.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Harry T Whelan, MD
Giant Cell Glioblastoma, Glioblastoma
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back…
- Conditions
- Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma
- Trial name
- NCT01609790
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 244 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)